The impact of PROSTAMER* on sarcoma LI growth in mice
Article published in Urologia Polska 2002/55/2.

authors

Ewa Skopińska-Różewska ¹, Halina Strzelecka ², Beata Białas-Chromiec ¹, Ewa Sommer ¹, Małgorzata Filewska ¹, Agnieszka Bazylko ², Henryk Skurzak ³: ¹ Zakład Diagnostyki Laboratoryjnej i Immunologii Instytutu Gruźlicy i Chorób Pluć w Warszawie
Kierownik zakładu: prof, dr hab. Ewa Skopińska-Różewska
² Katedra i Zakład Farmakognozji Akademii Medycznej w Warszawie
Kierownik zakładu: prof, dr hab. Halina Strzelecka
³ Zaklad Immunologii Centrum Onkologii Instytutu im. M. Skłodowskiej-Curie w Warszawie
Kierownik zakładu: prof, dr hab. Jan Steffen

keywords

sarcoma LI, mouse, shark liver oil, pumpkin seed oil

summary

Introduction. Prostamer® is a combine (1:1) product of Prostogal (pumpkin seed oil) and Ekogal (shark liver oil), which arc registered as separate preparations. It is recommended as adjuvant therapy of BPH early stages. The study was aimed at evaluating the impact of Prostamer® on growth and vascularisation in cancer mouse model.

LI sarcoma cells were implanted to syngenic mice intracutaneusely (cutaneus angiogenesis test, evaluation after 3 days, outcome verification with computer software for graphic analysis „Mice Observer\" performed as a part of KBN 7TO8AO5016 grant) or subcutaneously (tumour growth follow-up and haemoglobin concentration on 14th day as a blood supply measure). Mice were administered with evaluated preparations in doses of 4 or 8 ul.

Results. Tumour onset was later in mice administered with Prostamer® as compared to control group and additionally the tumour volume was significantly lower. High Prostamer® dose resulted also in decrease of cutaneous angiogenesis lest induced by intraculaneously implanted tumour cells. There was no difference in blood supply, compared to the control, assessed on 14th day after tumour cells implantation. No significant difference in tumour volume as compared to control (mice feeded with single ingredients of Prostamer* preparation) was observed.

Conclusions. In animal model Prostamer® in therapeutic doses or twice the therapeutic doses has shown antineoplastic activity, which in case of higher closes might resulted from suppressing of early angiogenesis.

references

1. Borkowski B: Rośliny lecznicze w filoterapii. IRiPZ, wyd. II, Poznań 2000; 308.
2. Physician ReferenI Desk (PDR) for Herbal Medicines, Medical Economic Company 1999; 784-785.
3. Berges RR, Windier J, Trampish HJ, Senge T: Randomised placebo-controlled, double-blind clinical trial of b-sitostero! in patients with benign prostatic hyperplasia.Lancet 1995, 345:1529-1532.
4. Hansel R, Slicher O, Stcinegger E: Phaimakognosie - Phy-topharmazie 6 aufi. Berlin; Heidelberg; New York; Barcelona; Hong-Kong; London; Mailand; Paris; Singapur; Tokio Springer Verl. 1999 Hansel R kap. 3 Lipide 239-265.
5. Loew D, Rietbrock N: Phytophaimaka in Forschung und Klinscher Anwendung Sleinkopf. Darmstadt 1995 Koch E kap I Pharmakologic und Wirkmechanismen von Extrakten aus Sabalfruchten (Sabal fructus), Brennesselwurzeln (Urti-eae radix) und Kurbissamen (cucurbitae peponis semen) bei der Bchandlung der Benignen Prostatahyperplasie, 57-79.
6. Santer M: Phytochemische und andere Untersuchungen von Cucurbita pepo L., Somen mit Hinblick auf mógliche prosta-tropwirksame Inhaltstoffe Dissertation F. Univ Berlin. 1984.
7. Schilcher H: Phytophaimaka zur Therapie von Prostataer-krankungen. Z Angew Phytother 1981; 2; 14-16.
8. Schilcher H, Dunzenclorler U, Ascali F: Delta 7 sterole das prosiatatrope Wirkprinzinp in Kurbissamen. Urologie 1987; 27; 316-19.
9. Schilcher H: Phyloterapie in der Urologie. Hippocrates Stut-tgard 1981; 84-88.
10. Loy V, Hubotter R, Bauer HW: Die Entzundungen, ein Wachxlumreiz der benignen Hyperplasie der prostata, wg Bauer H. W. Brenigne Prostathyperplasie Zuckschncrcd. Miinchen 1988; 3-12.
11. Reuter H: Therapie mit Phytophaimaka, Gustav Fischer Verlag. Stuttgard 1977; 152-158.
12. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Mallace M, Gibelin B; Comparison offinasterid (Pro-sear) a 5a reductase inhibitor and various commercial plant extracts in vitro and in vivo 5a reductase inhibitor!. Prostate 1993; 22; 43-51.
13. Schulz V, Hansel R: Rationale Phyloterapie Ralgeber fur die drztiche Praxis. Springer Verlag 1995.
14. Krotkiewski M: Pizeciwnowolworowe działanie alkiloglicero-li. Terapia 2001; 3; 23-24.
15. Snyder F. Wood R: Alky! and alk-1-enyi ethers of glycerol in lipids from normal and neoplastic human tissues. Cancer Res 1969; 21; 241-257.
16. Brohult A, Brohult J, Brohult S: Regression of tumor growth after administration of alkoxyglycerols. Acta Obst Gynecol Scan 1978; 57; 79-83.
17. Skopińska-Różewska E, Krotkiewski M, Sommer E, Rogala E, Filewska M, Bialas-Chromiec B, Pastewka K, Skurzak H: Inhibitory effect of shark liver oil on cutaneous angiogene-sis induced in Balb/c mice by syngenic sarcoma L-l, human urinaiy bladder and human kidney tumour cells. Oncol Rep 1999; 6; 1341-1344.
18. Sommer E, Krotkiewski M, Langlort R, Skopińska-Różewska E: Wpływ oleju z wątroby rekina na odczyn skórnej an-giogenezy indukowanej u myszy komórkami ludzkiego raka płuca. Terapia 2001; 9; 7-8.
19. Sommer E, Skopińska-Różewska E, Filewska M, Kupis W. Bogdan J, Seweryniak W, Rudziński P, Caban M, Dorosz W. Gątarek J, Usiekniewicz J, Sawicka E, Bartosik W, Langforl R, Słodkowska J: Pobudzający wpływ oleju z nasion wiesiołka dziwnego (Oenothera paradoxa) na reakcje skórnej angio-genezy indukowaną u myszy komórkami ludzkich raków płuc w: Wpływ ksenobiotyków na układ odpornościowy, red. A. K. Siwicki. IRS, Olsztyn 1997; 153-158.
20. Sidky Y, Auerbach R: Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-versus-host reaction. J Exp Med 1975; 141; 1084-1089.
21. Skopińska-Różewska E, Janik P, Przybyszewska M, Sommer E, Bialas-Chromiec B: Inhibitoiy effect of theobromine on induction of angiogenesis and VEGF mRNA expression in v-raf transfectants of human urothelial cells HCV-29. Int J Mol Med 1998; 2; 649-652.
22. Snitkowska E, Domański J, Balan B, Sommer E, Skopińska-Różewska E: Program komputerowej analizy obrazów Mouse Observer i jego zastosowanie do oceny wyników uzyskanych w teście skórnej angiogenezy u myszy. Terapia 2001; 9; 9-10.
23. Chorostowska-Wynimko J, Skopińska-Różewska E, Krotkiewski M, Radomska-Lesniewska D: Wpływ podawania myszom pałeczek kwasu mlekowego i oleju z wątroby rekina na aktywność chemokinetyczną ich splenocytów w hodowli in vitro. Terapia 2001; 9; 29-32
24. Chorostowska-Wynmko J, Krotkiewski M, Radomska-Lesniewska D, Sokolnicka I, Skopińska-Różewska E: The synergistic effect of lactic acid bacteria and alkyloglycerols on humoral immunity in mice. Int J Tissue React 2001; 3; 81-87.
25. Jackson JK, Burl HM, Oktaba AM, Hunter W, Scheid MP, Mouhajir F, Lauener RW, Shen Y, Salari H, Duronino V: The antineoplastic ether lipids-phosphonate, selectively induces apoptosis in human leukemic cells and exhibits antiangio-genic and apoptotic activity on chorioallantoic membrane of the chick embiyo. Cancer Chemother. Pharmacol. 1988; 41; 326-32.
26. Mollonedo F; Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine).: Molecular structure requirements, cellular uptake, and protection by bcl-2 and bcl-xl. Cancer Res 1997; 57; 1320-8.
27. Civoli F. Daniel L: Quarternaiy ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines. Cancer Chemother. Pharmacol 1998; 42; 319-26.

correspondence